Text Size

Dual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified Treatment

This study has been completed.
Sponsor:
Information provided by:
University of Konstanz
ClinicalTrials.gov Identifier:
NCT00783185
First received: October 30, 2008
Last updated: January 11, 2010
Last verified: October 2008
History of Changes

October 30, 2008
January 11, 2010
January 2006
June 2009   (final data collection date for primary outcome measure)
PANSS Positive and Negative Symptom Scale [ Time Frame: post intervention, six months follow-up ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00783185 on ClinicalTrials.gov Archive Site
Urinstatus for cannabinoids [ Time Frame: weekly during and post intervention, follow-up ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Dual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified Treatment
Dual Diagnosis Psychosis and Substance Abuse: Short- and Middle-term Changes in Symptomatology After Visiting a Group Education Programme to Reduce Consumption of Cannabis

Intention of the study is to examine, if the symptomatology of dual diagnosis patients is less severe after a special indication training for reduction of cannabis consumption in comparison to unspecified trainings.

Point of interest is psychopathology and consumerism.

Dual diagnosis patients (psychosis and cannabis abuse) account for more clinical admissions than single diagnosis patients.

Cannabis misuse is a known risk factor for recurrence of psychosis.

A specified intervention on the basis of a manual for schizophrenic substance abusers is administered to inpatients in a specialized unit for young schizophrenic patients in a psychiatric hospital.

The control group, same indication (psychotic disorder and cannabis misuse) receives social competence training (specified for schizophrenic patients as well).

Admission to groups is randomly.
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Psychotic Disorders
  • Marijuana Abuse
  • Intervention
  • Behavioral: Cannabis-Consumption-Reduction-Training
    8 sessions within 4 weeks (twice a week, 45 minutes each) Cognitive behavioral therapy with focus on cannabis abuse
  • Behavioral: Social competence Training
    8 sessions within 4 weeks (twice a week, 45 minutes) training to develop and ameliorate social competences
  • Experimental: ACT
    Anti-Cannabis-Consumption-Training
    Intervention: Behavioral: Cannabis-Consumption-Reduction-Training
  • Active Comparator: CG
    Control group
    Intervention: Behavioral: Social competence Training
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
January 2010
June 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinical diagnosis of schizophrenia and disorders with psychotic features
  • Misuse of cannabis during 12 months preceding admission to hospital

Exclusion Criteria:

  • Not able to attend training twice a week for 45 minutes (concentration, attention, psychotic symptoms, agitation)
  • Discharge from hospital before completion of training
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00783185
CRET
No
Hans Watzl, Dr., University of Konstanz
University of Konstanz
Not Provided
Principal Investigator: Hans Watzl, Dr. University of Konstanz
University of Konstanz
October 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP